Back to Journals » OncoTargets and Therapy » Volume 10

VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma

Total article views   HTML views PDF downloads Totals
8,442 Dovepress* 7,345+ 1,416 8,761
PubMed Central* 1,097 282 1,379
Totals 8,442 1,698 10,140
*Since 6 January 2017
Total mentioned Facebook Delicious Reddit Twitter Others
4 0 0 0 2 2

View citations on PubMed Central and Google Scholar